Morgan Stanley has raised its price target on Alnylam Pharmaceuticals. The new target price is $400, although other outlets report different price targets from other analysts. The company's stock is being discussed in terms of its growth potential, with some outlets considering it a strong option for aggressive growth and others adjusting their price targets.